Comparison of 2 different inhaled epoprostenol dosing strategies for acute respiratory distress syndrome in critically ill adults: Weight-based vs fixed-dose administration
- PMID: 35877207
- DOI: 10.1093/ajhp/zxac192
Comparison of 2 different inhaled epoprostenol dosing strategies for acute respiratory distress syndrome in critically ill adults: Weight-based vs fixed-dose administration
Abstract
Purpose: Inhaled epoprostenol (iEPO) is a viable, temporizing option for acute respiratory distress syndrome (ARDS), although the optimal iEPO dosing strategy remains inconclusive. The purpose of this study was to evaluate oxygenation and ventilation parameters in a comparison of weight-based and fixed-dose iEPO in adult patients with moderate-to-severe ARDS.
Methods: A retrospective cohort study was conducted at 2 academic medical centers in adult intensive care unit (ICU) patients administered either fixed-dose or weight-based iEPO for moderate-to-severe ARDS. The primary endpoint was the highest recorded change in the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) within 4 hours of baseline. Secondary analyses compared responder rates within 4 hours of initiation, oxygenation and ventilation parameters, in-hospital mortality rates, mechanical ventilation duration, length of stay (ICU and hospital), and tracheostomy rates between the study groups.
Results: A total of 294 patients were included, n = 194 with 100 (34.0%) and 194 (66.0%) in the weight-based and fixed-dose iEPO groups, respectively. The mean (SD) change in the highest recorded PaO2/FiO2 value from baseline up to 4 hours after initiation in the fixed-dose and weight-based groups was 81.1 (106.0) and 41.0 (72.5) mm Hg, respectively (P = 0.0015). The responder rate at 4 hours after iEPO initiation was significantly higher in the fixed-dose group (69.9%) than in the weight-based group (30.1%) (P = 0.02). The only predictor of response was fixed-dose administration (odds ratio, 3.28; 95% confidence interval, 1.6-6.7; P = 0.0012). Clinical outcomes were comparable between the groups.
Conclusion: Fixed-dose iEPO was associated with significantly higher response rates then weight-based iEPO during the first 4 hours of therapy. Fixed-dose iEPO is a more convenient strategy than weight-based approaches.
Keywords: acute respiratory distress syndrome; critically ill; inhaled epoprostenol; inhaled prostacyclin; intensive care.
© American Society of Health-System Pharmacists 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Comparison of Fixed-Dose Inhaled Epoprostenol and Inhaled Nitric Oxide for Acute Respiratory Distress Syndrome in Critically Ill Adults.J Intensive Care Med. 2021 Apr;36(4):466-476. doi: 10.1177/0885066620906800. Epub 2020 Mar 5. J Intensive Care Med. 2021. PMID: 32133901
-
Evaluation of Continuous Inhaled Epoprostenol in the Treatment of Acute Respiratory Distress Syndrome, Including Patients With SARS-CoV-2 Infection.Ann Pharmacother. 2022 Oct;56(10):1093-1099. doi: 10.1177/10600280211069182. Epub 2022 Jan 13. Ann Pharmacother. 2022. PMID: 35021923
-
Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients.J Crit Care. 2013 Oct;28(5):844-8. doi: 10.1016/j.jcrc.2013.03.006. Epub 2013 May 14. J Crit Care. 2013. PMID: 23683572
-
The role of inhaled prostacyclin in treating acute respiratory distress syndrome.Ther Adv Respir Dis. 2015 Dec;9(6):302-12. doi: 10.1177/1753465815599345. Epub 2015 Aug 20. Ther Adv Respir Dis. 2015. PMID: 26294418 Review.
-
A Narrative Review on the Administration of Inhaled Prostaglandins in Critically Ill Adult Patients With Acute Respiratory Distress Syndrome.Ann Pharmacother. 2024 May;58(5):533-548. doi: 10.1177/10600280231194539. Epub 2023 Aug 17. Ann Pharmacother. 2024. PMID: 37589097 Review.
Cited by
-
Inhaled Prostacyclins for Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis.Crit Care Explor. 2023 Jun 8;5(6):e0931. doi: 10.1097/CCE.0000000000000931. eCollection 2023 Jun. Crit Care Explor. 2023. PMID: 37303944 Free PMC article. Review.
-
Inhaled epoprostenol for management of acute respiratory failure and pulmonary vascular disease.Pulm Pharmacol Ther. 2025 Jun 11;90:102374. doi: 10.1016/j.pupt.2025.102374. Online ahead of print. Pulm Pharmacol Ther. 2025. PMID: 40513981 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources